Performance metrics of PRIMA-PI, FLIPI, and FLIPI-2
| . | All patients . | Patients ≤60 y . | Patients >60 y . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | PRIMA-PI . | FLIPI . | FLIPI-2 . | PRIMA-PI . | FLIPI . | FLIPI-2 . | PRIMA-PI . | FLIPI . | FLIPI-2 . |
| High-risk patients, n (%) | 141/475 (30) | 307/669 (46) | 211/568 (37) | 79/316 (25) | 119/422 (28) | 79/364 (22) | 62/159 (39) | 188/247 (76) | 132/204 (65) |
| PFS | |||||||||
| Patients evaluable, n | 472 | 661 | 563 | 313 | 416 | 359 | 159 | 245 | 204 |
| 5-y PFS (95% CI), % | 39 (30-50) | 48 (42-55) | 44 (37-53) | 50 (36-69) | 50 (39-63) | 52 (39-69) | 31 (21-46) | 47 (40-55) | 42 (34-52) |
| Sensitivity (SE), % | 43 (4.3) | 66 (3.5) | 58 (3.9) | 32 (6.0) | 42 (5.4) | 30 (5.3) | 53 (5.8) | 84 (3.5) | 82 (4.2) |
| Specificity (SE), % | 80 (3.3) | 60 (3.3) | 68 (3.4) | 84 (3.9) | 79 (3.5) | 83 (3.6) | 73 (5.7) | 33 (4.8) | 47 (5.5) |
| c-index (SE) | 0.73 (0.03) | 0.72 (0.03) | 0.73 (0.03) | 0.72 (0.06) | 0.74 (0.04) | 0.71 (0.05) | 0.71 (0.05) | 0.65 (0.06) | 0.75 (0.05) |
| OS | |||||||||
| Patients evaluable, n | 475 | 669 | 568 | 316 | 422 | 364 | 159 | 247 | 204 |
| 5-y OS (95% CI), % | 72 (63-81) | 79 (74-84) | 78 (72-84) | 84 (73-97) | 83 (75-92) | 85 (75-96) | 61 (50-76) | 76 (70-83) | 75 (67-83) |
| Sensitivity (SE), % | 59 (7.3) | 75 (5.3) | 72 (6.3) | 43 (13.3) | 57 (10.8) | 44 (12.5) | 67 (8.3) | 83 (5.4) | 84 (6.2) |
| Specificity (SE), % | 77 (2.8) | 54 (2.7) | 63 (2.8) | 80 (3.5) | 73 (3.2) | 80 (3.1) | 72 (4.6) | 29 (3.7) | 41 (4.4) |
| c-index (SE) | 0.77 (0.05) | 0.77 (0.04) | 0.78 (0.04) | 0.71 (0.10) | 0.75 (0.07) | 0.68 (0.10) | 0.74 (0.06) | 0.65 (0.07) | 0.74 (0.07) |
| . | All patients . | Patients ≤60 y . | Patients >60 y . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | PRIMA-PI . | FLIPI . | FLIPI-2 . | PRIMA-PI . | FLIPI . | FLIPI-2 . | PRIMA-PI . | FLIPI . | FLIPI-2 . |
| High-risk patients, n (%) | 141/475 (30) | 307/669 (46) | 211/568 (37) | 79/316 (25) | 119/422 (28) | 79/364 (22) | 62/159 (39) | 188/247 (76) | 132/204 (65) |
| PFS | |||||||||
| Patients evaluable, n | 472 | 661 | 563 | 313 | 416 | 359 | 159 | 245 | 204 |
| 5-y PFS (95% CI), % | 39 (30-50) | 48 (42-55) | 44 (37-53) | 50 (36-69) | 50 (39-63) | 52 (39-69) | 31 (21-46) | 47 (40-55) | 42 (34-52) |
| Sensitivity (SE), % | 43 (4.3) | 66 (3.5) | 58 (3.9) | 32 (6.0) | 42 (5.4) | 30 (5.3) | 53 (5.8) | 84 (3.5) | 82 (4.2) |
| Specificity (SE), % | 80 (3.3) | 60 (3.3) | 68 (3.4) | 84 (3.9) | 79 (3.5) | 83 (3.6) | 73 (5.7) | 33 (4.8) | 47 (5.5) |
| c-index (SE) | 0.73 (0.03) | 0.72 (0.03) | 0.73 (0.03) | 0.72 (0.06) | 0.74 (0.04) | 0.71 (0.05) | 0.71 (0.05) | 0.65 (0.06) | 0.75 (0.05) |
| OS | |||||||||
| Patients evaluable, n | 475 | 669 | 568 | 316 | 422 | 364 | 159 | 247 | 204 |
| 5-y OS (95% CI), % | 72 (63-81) | 79 (74-84) | 78 (72-84) | 84 (73-97) | 83 (75-92) | 85 (75-96) | 61 (50-76) | 76 (70-83) | 75 (67-83) |
| Sensitivity (SE), % | 59 (7.3) | 75 (5.3) | 72 (6.3) | 43 (13.3) | 57 (10.8) | 44 (12.5) | 67 (8.3) | 83 (5.4) | 84 (6.2) |
| Specificity (SE), % | 77 (2.8) | 54 (2.7) | 63 (2.8) | 80 (3.5) | 73 (3.2) | 80 (3.1) | 72 (4.6) | 29 (3.7) | 41 (4.4) |
| c-index (SE) | 0.77 (0.05) | 0.77 (0.04) | 0.78 (0.04) | 0.71 (0.10) | 0.75 (0.07) | 0.68 (0.10) | 0.74 (0.06) | 0.65 (0.07) | 0.74 (0.07) |